BeadArray-based solutions for enabling the promise of pharmacogenomics.
A "one-size-fits-all" approach continues to characterize today's healthcare paradigm. But emergent rules, information, genomics tools, and economics are driving a fundamental and inevitable shift to a more personalized world of medicine. In this new world, the interests of insurers, regulators, suppliers, healthcare providers, and most important, patients, will have converged. The new goal will be the right treatment for the right individual at the right time. In this world, personalized medicine, through pharmacogenomics (PGx), will be the new healthcare paradigm. We will briefly examine healthcare trends and current opportunities for PGx development. We will then demonstrate how microarray technologies-among them bead-based approaches-have emerged as a key enabler for bringing home the promise of PGx.
Fan
Jian-Bing
JB
Illumina, San Diego, CA 92121, USA.
Hu
Sean X
SX
Craumer
William C
WC
Barker
David L
DL
D001709:Biotechnology / Q000295:instrumentation* / Q000379:methods; D045744:Cell Line, Tumor; D004247:DNA / Q000378:metabolism; D019175:DNA Methylation; D018076:DNA, Complementary / Q000378:metabolism; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics / Q000295:instrumentation* / Q000379:methods*; D020641:Polymorphism, Single Nucleotide; D012313:RNA / Q000737:chemistry / Q000378:metabolism; D016896:Treatment Outcome
D018076:DNA, Complementary; D012313:RNA; D004247:DNA